According to the Market Statsville Group (MSG), the Global Endogenous Peptide Substances Market size is expected to grow at a CAGR of 7.2% from 2023 to 2033.

Endogenous peptide substances are naturally occurring short chains of amino acids produced within the body, synthesized by cells and tissues, and help to regulate numerous biological functions. Endogenous peptides are found throughout the human body, including the brain, gastrointestinal tract, and immune system, and their functions are cell signaling, hormone regulation, neurotransmission, and neuromodulation. Endogenous peptides have application in the immune system, act as cytokines to coordinate immune responses, or as antimicrobial peptides to defend against infections.

The demand for endogenous peptide substances in the market is being driven by the increasing awareness of endogenous peptide function in physiological processes. Researchers and healthcare professionals are focused on exploring the use of endogenous peptides in the development of novel treatments for a wide range of medical conditions, such as neurological disorders, metabolic diseases, and immune-related disorders. Thus, the aforementioned factors accelerated the demand for endogenous peptide substances as both diagnostic tools and therapeutic agents. The growing aging population and prevalence of age-related diseases and conditions accelerated the endogenous peptides market growth. Additionally, the demand for more personalized and precision medicine approaches has led to increased investment in therapies that can target specific molecular pathways, boosting the demand for endogenous peptide substance market over the forecast period. The advancements in peptide synthesis and manufacturing technologies to produce endogenous peptides at a larger scale have led to a positive outlook for market demand.

Request Sample Copy of this Report: https://www.marketstatsville.com/request-sample/endogenous-peptide-substances-market?utm_source=free&utm_medium=harsh                                                                      

Endogenous Peptide Substances Market Key Players, 2023

The Major key players in the global endogenous peptide substances market are:

• Cipher Pharmaceuticals Inc.
• Biosynth Carbosynth 
• Abbexa 
• Phoenix Pharmaceuticals
• Lannett Co. Inc.
• Pfizer
• Johnson & Johnson
• Peptide Institute
• Creative Peptides
• Endo International Plc
• Assertio Therapeutics Inc.

Recent Developments

• In April 2023, Assertio Holdings, Inc. acquired Spectrum and its commercial capabilities and ROLVEDON, a novel long-acting G-CSF product. The acquisition will expand its diverse therapeutic categories, and ability to continue growth in the growing endogenous peptide substances market.
• In December 2020, Endo International plc acquired BioSpecifics Technologies Corp. The acquisition enhanced Endo International’s product offerings and expanded its geographical reach catering to various customers.

Direct Purchase Report: https://www.marketstatsville.com/buy-now/endogenous-peptide-substances-market?opt=3338&utm_source=free&utm_medium=harsh

Report Scope of the Global Endogenous Peptide Substances Market

This market research study categorizes the endogenous peptide substances market-based on type and application at the global, regional, and country levels.

By Type Outlook (Sales, USD Million, 2019-2033)

• Neuropeptides
• Hormones
• Cytokines
• Peptide Hormones
• Bioactive Peptides

By Application Outlook (Sales, USD Million, 2019-2033)

• Research
• Medicine
• Others

By Region Outlook (Sales, USD Million, 2019-2033)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Italy
  • France
  • UK
  • Spain
  • Poland
  • Russia
  • The Netherlands
  • Norway
  • Czech Republic
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Malaysia
  • Thailand
  • Singapore
  • Australia & New Zealand
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Rest of South America
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Northern Africa
  • Rest of MEA
     Request For Report TOC: https://www.marketstatsville.com/table-of-content/endogenous-peptide-substances-market

Endogenous Peptide Substances Market Segmental Analysis, 2023-2033

Based on type, the market is divided into neuropeptide, hormones, cytokines, peptide hormones, and bioactive peptides. The neuropeptide is expected to dominate the market in 2023. The growing researchers exploration in treating neurological disorders like Alzheimer's and Parkinson's disease, mental health conditions, and chronic pain management is driving demand for neuropeptides segment growth in the market. According to the Alzheimer's Association, currently, there are over 6 million individuals in the United States living with Alzheimer's disease. The Alzheimer's Association report stated that by the year 2050, this figure is expected to increase significantly to almost 13 million. Similarly, as per the Parkinson's Foundation, at present, there are nearly one million individuals in the United States diagnosed with Parkinson's disease (PD). It is anticipated that by the year 2030, this number will increase to approximately 1.2 million. Parkinson's stands as the second most prevalent neurodegenerative disorder in the U.S., following Alzheimer's disease. Thus, the surging prevalence of Alzheimer's and Parkinson's disease, and other mental health conditions across the globe has significantly fostered the market’s growth over the forecast period. The growing aging population that simultaneously accelerates age-related neurological conditions is another factor contributing to the market’s growth.